Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 87,627 shares, a drop of 36.2% from the July 15th total of 137,249 shares. Based on an average trading volume of 19,324 shares, the days-to-cover ratio is presently 4.5 days. Currently, 5.8% of the company’s stock are sold short.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Down 4.4%

Shares of NASDAQ:APVO opened at $2.81 on Tuesday. The firm has a fifty day moving average of $4.33 and a two-hundred day moving average of $5.03. Aptevo Therapeutics has a 12-month low of $2.81 and a 12-month high of $48.78. The firm has a market capitalization of $4.27 million, a P/E ratio of -0.01 and a beta of 1.65.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.57) by $0.26. Equities research analysts expect that Aptevo Therapeutics will post -23.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Aptevo Therapeutics has a consensus rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.